Expert Interview
Second View: Discussing Neurocrine Bioscience's FDA approval for CRENESSITY, a treatment for congenital adrenal hyperplasia (CAH) used alongside glucocorticoids to control androgen levels and reduce the need for high-dose steroid therapy.
Ticker(s): NBIXInstitution: Karolinska University Hospital
- Associate Professor of Endocrinology at Karolinska University Hospital, Stockholm, Sweden & Director of the Adrenal Unit at Department of Endocrinology.
- Research focuses on Congenital adrenal hyperplasia (249 peer reviewed publications, h-index of 41, half of the publications deal with CAH)
- PI on several academic and industrial sponsored studies.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
